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Abstract
Embryonic stem cells (ESCs) generated from the in-vitro culture of blastocyst stage embryos are known as equivalent to
blastocyst inner cell mass (ICM) in-vivo. Though several reports have shown the expression of germ cell/pre-meiotic (GC/
PrM) markers in ESCs, their functional relevance for the pluripotency and germ line commitment are largely unknown. In the
present study, we used mouse as a model system and systematically analyzed the RNA and protein expression of GC/PrM
markers in ESCs and found them to be comparable to the expression of cultured pluripotent cells originated from the germ
line. Further, siRNA knockdown experiments have demonstrated the parallel maintenance and independence of pluripotent
and GC/PrM networks in ESCs. Through chromatin immunoprecipitation experiments, we observed that pluripotent cells
exhibit active chromatin states at GC marker genes and a bivalent chromatin structure at PrM marker genes. Moreover, gene
expression analysis during the time course of iPS cells generation revealed that the expression of GC markers precedes
pluripotency markers. Collectively, through our observations we hypothesize that the chromatin state and the expression of
GC/PrM markers might indicate molecular parallels between in-vivo germ cell specification and pluripotent stem cell
generation.
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Introduction
The capacity of long-term self-renewal and the unique ability to
differentiate into all three germ layer cell types (ectoderm,
endoderm and mesoderm) define pluripotency. According to the
source of cells used for the establishment of pluripotent cells, one
can currently distinguish between the following pluripotent cell
lines: (1) embryonic stem cells (ESCs) derived from the inner cell
mass of mouse blastocysts at embryonic day 3.5 (E3.5) [1,2], (2)
embryonic germ cells (EGCs) cultured from primordial germ cells
(PGCs) that colonize the genital ridge at E12.5 [3,4], (3)
embryonal carcinoma cells (ECCs) isolated from germ-cell tumors
of either testis or ovary [5], (4) germ line stem cells isolated from
mouse neonatal and adult testis (GSCs and maGSCs, respectively)
[6,7] and (5) induced pluripotent stem cells (iPSCs), derived from
reprogramming somatic cells by ectopic expression of defined
transcription factors [8]. All the above mentioned cultured
pluripotent cell lines (EGCs, ECCs, GSCs, and maGSCs) have a
germ-cell origin, except ESCs, whose origin is not clearly
understood. Although these cell lines have different molecular
profiles mostly due to their developmental stage of isolation, they
share the expression of germ cell/pre-meiotic (GC/PrM) markers
that may indicate a germ-cell origin [9].
During embryonic development, the specification of PGCs is
crucial for the development of the germ line, which is finally
destined to give rise to the totipotent zygote upon fertilization.
Prior to gastrulation, the precursors of primordial germ cells arise
in the E6.25 proximal epiblast from 4–8 cells positive for the
transcriptional repressor Blimp1 [10,11]. These Blimp1-positive
cells continuously proliferate and start to express other PGC
markers such as Fragilis and Stella by E7.5. Thereafter, PGCs
initiate migration and colonization of the genital ridge and
increase their number to approximately 4000 by E12.5 [12,13].
Further development of PGC/germ cells to mature spermatozoa
or oocytes depends on the coordinated genetic and epigenetic
events [14]. Interestingly, several studies have demonstrated the
expression of some of the GC/PrM markers like Blimp1, Stella,
Fragilis, Piwil2, Dazl and MVH in ES cells at the RNA level
[15,16,17], raising the possibility that ES cells might originate
from the germ line [9].
In the present study, using mouse as a model system, we have
systematically analyzed the expression of GC/PrM markers in ES
cells compared to germ line origin cultured pluripotent cells like
EGCs, ECCs, GSCs and maGSCs and found comparable
expression at the RNA and protein level. Moreover, we show
the expression of Stella, Dazl and MVH in preimplantation
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from germ cell-specific networks in ES cells. Interestingly,
chromatin immunoprecipitation (ChIP) analysis revealed that ES
cells exhibit active chromatin states at GC marker genes and a
bivalent chromatin structure at PrM marker genes. Further, gene
expression analysis during iPSC generation revealed that the
expression of GC markers precedes pluripotency markers. Collec-
tively, our data indicates the possible link between in-vivo germ cells
specification and in-vitro pluripotent stem cells generation.
Materials and Methods
Cell culture
Derivation and maintenance of male mouse ESC and maGSC lines
from different genetic backgrounds (129Sv and C57BL/6) were
described previously [18]. The female ESC line ES Rosa26 was
generated from Rosa26-LacZ transgenic mouse line as described for
MPI-VI, a previously generated female ESC line [19]. iPS cells (O18)
were a kind gift from Prof. Rudolf Jaenisch [20]. All above cell lines
including EGC line (EG 1) and parthenogenetic cells were maintained
in standard ESC culture conditions. ECC cell line (F9) protein extract
was provided by Mr. Peter Christalla, Goettingen. For knockdown
experiments, ES cells were seeded in KO-DMEM supplemented with
KO-serum replacement (Invitrogen) at a density of 2610
5 cells/ml on
feeder layer. After 5 h of plating, the cells were transfected with either
Dazl siRNA (NM_010021.4_stealth_199, _726, _1056, Invitrogen) or
MVH siRNA (NM_001145885.1_stealth_83, _922, _1599, Invitrogen)
or Oct3/4 siRNA (NM_013633_Stealth_356, _463, _727, Invitrogen)
or scrambled siRNA (Control siRNA,Invitrogen) using Lipofectamine-
2000 (Invitrogen) according to manufacturer’s instructions. After 3 h of
transfection, the medium was changed to standard ES culture medium
and allowed to grow for 24 h. The next day, transfection was repeated
and cells were harvested after additional 24 h of culture.
All animal experimentations were reviewed and approved by
the Institutional Animal Care and Use committee of the University
of Goettingen (Approval ID: 33.9.42502-097/06).
Generation of iPS cells
We used Yamanaka factors (retroviral expression vectors for
Oct3/4, Sox2, Klf4, c-Myc) to generate iPS cells [8]. For
reprogramming studies, embryonic fibroblasts isolated from
transgenic Nanog-EGFP mice [21] were transduced with retroviral
particles as previously described [8]. To establish iPS cell lines,
colonies which appeared after 10 days of virus infection were
picked manually and cultured in 24-well plates containing feeder
layer with standard ES medium and were monitored for the Nanog-
EGFP activation using invert microscope (Olympus). For time
course experiments, all cells from culture plates were collected on
days 0 (Control), 5-10, 12, 14, 16, 18, 20 and 22 after viral
infection for total RNA isolation.
RNA extraction, RT-PCR and qPCR
Total RNA was extracted from cells using Trizol Reagent
(Invitrogen) and from ,50 blastocysts using Picopure Kit
(Analytical Technology) following the manufacturers’ protocols.
Total RNA from blastocysts or 5 mg of total RNA from cells was
digested with DNaseI (Sigma) and used for cDNA synthesis using
the SuperScriptII system (Invitrogen). For qPCR analysis, diluted
cDNA (1/20) was used as a template in a Platinum SYBR Green
qPCR SuperMix-UDG with ROX (Invitrogen) and run in ABI
7900HT Real-Time PCR System (Applied Biosystems). Primers
used in RT-PCR and qPCR are listed in supplementary tables
(Tables S1, S2, S3).
Protein extraction and Western blotting
Proteins were extracted from cells and tissues using lysis buffer
(10 mM Tris–HCl (pH 8.0), 1 mM EDTA, 2.5% SDS, 100 mM
PMSF) containing protease inhibitor cocktail (Roche). Protein
samples were resolved on 4–12% SDS-PAGE and transferred onto
nitrocellulose membrane (Amersham Biosciences). Membranes
were processed using standard Western blot protocols, and signals
detected using a chemiluminescent kit (Santa Cruz Biotechnology).
Antibody sources are listed in supplementary tables (Table S5).
Early-stage-embryo collection, immunocytochemistry,
and alkaline phosphatase staining
Early stage embryos collected from the oviduct or uterus of
pregnant CD-1 mice were used for whole-mount immunostaining
as described previously [22]. Immunostained embryos were
mounted on cavity microscope slides using Vectashield DAPI
mounting medium (Vector Laboratories) and images were
acquired using an Olympus confocal microscope. Immunostaining
on iPS cells using SSEA1 antibody was performed as previously
described [23]. Alkaline phosphatase (AP) staining was performed
according to manufacturer’s protocol (Sigma).
Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) was performed
essentially as previously described [23]. Briefly, cultured wild-type
ESCs were cross-linked with 1% formaldehyde and briefly
incubated in lysis buffer followed by sonication (Branson Sonifier
250). Soluble chromatin was pre-cleared with protein-A sepharose
beads and incubated with and without (negative-control) antisera
(3–5 mg) directed against H3K4me3, H3K9ac, H3K9me3, and
H3K27me3. Enriched DNA was analyzed by qPCR using SYBR
green (Invitrogen)-based PCR amplification with primers listed in
supplementary tables (Table S4). qPCR data from two or more
biological replicates were calculated and expressed as percentage
of input DNA precipitation. Antibodies used in ChIP are listed in
supplementary tables (Table S5).
Teratoma formation assay
Teratoma formation assay was performed as previously
described [24,25]. Briefly, iPS cells (1610
6 cells) were injected
subcutaneously into 8 to 10 weeks old female severe combined
immunodeficient RAG2
2/2ccc
2/2 mice lacking T, B, and
natural killer (NK) cells. Tumor growth was monitored weekly
by palpation and size was recorded using linear calipers. Animals
were sacrificed when a tumor diameter of 1 cm was reached.
Autopsies were performed and tumor tissue was placed in
phosphate-buffered 4% formalin for 16 h and then embedded in
paraffin. For histological analysis, the specimens were stained with
haematoxylin and eosin (HE).
Statistical Analysis
All qPCR data for RNA expression analysis (two or more
biological replicates) were calculated using standard curve method.
For statistical significance calculations, 2way ANOVA (GraphPad
Prism 4.0) test was used.
Results
Pluripotent stem cells express GC/PrM genes
To investigate whether GC/PrM gene expression is character-
istic of all known mouse pluripotent cells, we systematically
analyzed several pluripotent cells. Firstly, we examined GC/PrM
gene expression in male maGSCs and ESCs from different genetic
Germ-Cell Markers in Pluripotent Cells
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blotting (Fig. 1A). GC markers Stella and Fragilis were readily
detected in all cell types (Fig. 1A), including parthenogenetic cells
(Fig. 1B). Further, PrM markers Piwil2, Dazl, and MVH were
found to be expressed in all pluripotent cells, except ECCs
(Fig. 1A). Protein levels of GC/PrM markers were reduced or
absent in ESCs and maGSCs upon spontaneous differentiation
with retinoic acid for 20 days (Fig. 1B). Overmore, we analyzed
multipotent mesenchymal stem cells (MSCs) and could not detect
any expression of GC/PrM markers (Fig. 1B). We also performed
RT-PCR analysis for other PrM, meiotic, and post-meiotic
markers (Fig. 1C). Expression of PrM markers Stra8, Rnf17,
Rnh2, and Piwil2 was detected in all cells (Fig. 1C). Surprisingly,
meiotic markers Sycp3, Pgk2, and Creb3/4 were also detected in all
pluripotent cell lines (Fig. 1C). However, expression of several
other developmental markers such as post-meiotically expressed
Tp2, Theg, Gpx4, Prm1, and mature spermatozoan marker Cylc1
was undetectable as expected (Fig. 1C).
To determine whether the expression of GC/PrM markers is
specific to male pluripotent cells, we studied two female ES cell
lines, namely, MPI VI and ES Rosa26. Pluripotency of these cell
lines was confirmed by detecting the expression of the key
pluripotency markers Oct3/4 and Sox2 (data not shown). Both
female pluripotent cell lines were found to express all analyzed
GC/PrM markers with levels similar to those of male pluripotent
cells (Fig. 1D).
GC/PrM genes are also expressed in early embryogenesis
Next, we studied the expression of GC marker (Stella) and PrM
markers (Dazl and MVH) in early stages of mouse embryogenesis
(2-, 4-, 8-cell stages) by immunocytochemistry (ICC) (Fig. 2A).
Interestingly, we found Stella, Dazl and MVH to be expressed
throughout all stages of embryogenesis (Fig. 2A). To determine the
expression levels of GC/PrM markers at the blastocyst stage, we
performed qPCR on blastocyst stage embryos (Fig. 2B). In
agreement with our ICC results, all analyzed GC/PrM markers
(Fragilis, Dazl, MVH, and Stra8) were detected at the blastocyst
stage with transcript levels, that are, however, markedly lower than
those of pluripotency markers such as Oct3/4, Nanog, Lin28
(Fig. 2B).
Independency of pluripotent and GC/PrM networks in
ESCs
The widespread expression of GC/PrM markers in pluripotent
cells led us to study their influence on other GC/PrM and key
pluripotency markers (Fig. 3). Firstly, we down-regulated Dazl in
ES cells using siRNA and found an ,80–90% decrease at both the
RNA and protein level (Fig. 3A, B). In contrast, control siRNA
treated cells did not exhibit altered Dazl expression levels (Fig. 3A,
B). Then, we performed a qPCR-based analysis of expression
levels of key pluripotency markers and detected no significant
differences among control siRNA treated and Dazl siRNA treated
cells (Fig. 3C). Similarly, the expression of PrM markers MVH and
Stra8 did not change significantly, whereas GC markers (Stella and
Fragilis) showed significant up-regulation in Dazl down-regulated
cells (Fig. 3D). Similarly, ,70% down-regulation of MVH
expression (Fig. 3E, F) did not influence expression of key
pluripotency markers (Fig. 3G). Consistent with Dazl down-
regulation, MVH depletion had no effect on Dazl and Stra8, but
Stella and Fragilis were significantly up-regulated (Fig. 3H).
Conversely, we down-regulated Oct3/4 and studied the expression
of GC/PrM and pluripotency markers. The down-regulation of
Oct3/4 resulted in significant down-regulation of Klf4 expression,
whereas the expression of other pluripotent markers such as Nanog,
Zfp206, and Lin28 did not alter (Supplementary Fig. S1).
Furthermore, the down-regulation of Oct3/4 had no statistically
significant effect on the expression of GC/PrM markers
(Supplementary Fig. S1).
Active chromatin at GC marker gene promoter regions
and bivalent chromatin at PrM marker gene promoters in
ESCs and iPSCs
We hypothesized that the chromatin state at the promoter
regions of GC/PrM markers might elucidate their role in the
establishment/maintenance of pluripotency or lineage specifica-
tion in ESCs. We analyzed the ChIP sequencing data of mouse ES
cells, which is freely available [26] and found that the promoter
regions of GC markers Blimp1, Stella and Fragilis were enriched for
H3K4me3 indicating the transcriptionally active chromatin state,
as seen for Oct3/4 (Supplementary Fig. S2A). In contrast the
promoter regions of Dazl and MVH were decorated with both
H3K4me3 and H3K27me3, highlighting the bivalent chromatin
state, which is a hall mark of lineage specification genes, such as
Hoxa11 and Pax5 (Supplementary Fig. S2B). To further validate
these observations, gene specific histone modification profiles
(active: H3K4me3, H3K9ac; and repressive: H3K9me3,
H3K27me3) were analyzed by ChIP at the promoter regions of
GC markers Fragilis and Blimp1, and PrM markers Dazl and MVH,
and compared to the promoter regions of Oct3/4 (transcriptionally
active chromatin) and Hoxa11 and Pax5 (bivalent chromatin) in ES
cells (Fig. 4A). qPCR quantification of ChIP DNA showed that the
promoter regions of GC markers Fragilis and Blimp1 were enriched
for the activating modifications H3K4me3 and H3K9ac, but
depleted for the repressive modifications H3K9me3 and
H3K27me3, indicating a transcriptionally active chromatin similar
to key pluripotency Oct3/4 gene promoter (Fig. 4A). In contrast,
the promoters of PrM genes Dazl and MVH were enriched for both
active (H3K4me3 and H3K9ac) and repressive (H3K27me3)
modifications, representing the bivalent chromatin domain similar
to lineage specific genes (Hoxa11 and Pax5) (Fig. 4A). Moreover, we
also performed gene specific histone modification profiling in
established iPS cells [20] and found similar results like ES cells
(Fig. 4B).
GC markers emerge during early reprogramming of MEFs
into iPSCs
To further understand the role of GC/PrM markers during the
establishment and maintenance of pluripotency, we used ectopic
expression of the four Yamanaka factors (Oct4, c-Myc, Klf4, and
Sox2) for reprogramming of somatic cells to induced pluripotency.
Firstly, we reprogrammed MEFs isolated from Nanog-EGFP mice
and established four iPS lines (xu1, 2, 5, and 6), which are
morphologically similar to ES cells, activate the Nanog promoter-
driven EGFP expression, positive for AP staining, SSEA1
immunostaining and express endogenous Oct3/4 and Sox2
(Fig. 5A–D). The iPSC lines were further characterized by histone
modification, and DNA methylation profiling of key pluripotent
marker genes (data not shown). Finally, all the iPSC lines (xu1, 2, 5
and 6) were injected subcutaneously into immunodeficient mice.
Two recipients were used per cell line. In all mice, tumors were
observed and the mice had to be sacrificed between day 18 and
day 33 after injection. The tumors were identified as teratomas by
histological examination as exemplified for iPS cell lines xu2 and 6
(Supplementary Fig. S3). Then, we setup a time course experiment
and analyzed the expression levels of key pluripotency genes and
GC/PrM genes during the course of reprogramming as outlined in
figure 5E. Expression analysis using real time qPCR revealed
Germ-Cell Markers in Pluripotent Cells
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22413significant expression levels of key germ cell markers (Blimp1 and
Fragilis) at day 6 and a gradual increase to the levels seen in ES
cells by day 22 (Fig. 5F, G). Transcripts of Stella, another germ cell
marker, were significantly detectable at day 10 of reprogramming
andreachedlevelssimilarto thoseinEScellsbyday22.(Fig.5F,G).
In contrast, significant endogenous expression levels of the key
pluripotency markers Oct3/4 and Sox2 occurred only on day 12 of
reprogramming and showed expression levels typical for ES cells by
Figure 2. Expression analysis of GC/PrM genes in early embryogenesis. (A) Immunocytochemistry showing the expression of GC marker
(Stella) and PrM markers (Dazl and MVH) in pre-implantation embryos (2-cell, 4-cell, and 8-cell stage). DAPI was used as a counter stain to visualize the
nucleus. (B) Quantitative real time PCR analysis was used to evaluate the expression levels of GC (Fragilis), PrM (Dazl, MVH, Stra8) and pluripotency
markes (Oct3/4, Nanog, Lin28) in blastocysts. Expression levels were normalized to Sdha (a house keeping gene). The qPCR data of three biological
replicates (including three technical replicates each) were calculated and represented as a mean 6SD.
doi:10.1371/journal.pone.0022413.g002
Figure 1. Expression analysis of GC/PrM genes in pluripotent cell lines. (A) Expression of GC markers (Stella, Fragilis) and PrM markers
(Piwil2, Dazl, MVH) in maGSCs and ESCs (of 129Sv and C57BL/6 genetic backgrounds), iPSCs, EGCs and ECCs. (B) Western blot of GC marker (Stella)
and PrM markers (Dazl and MVH) in mouse mesenchymal stromal cells (MSC), parthenogenetic cells, ES and maGSC treated with retinoic acid for 20
days. Protein extract from ESCs was used as a positive control. (C) RT-PCR analysis showing the expression of PrM (Stra8, Rnf17, Rnh2 and Piwil2),
meiotic (Sycp3, Pgk2 and Creb3/4) and post-meiotic (Tp2, Prm1 and Cylc1) markers in maGSC and ESC (from different genetic backgrounds), as well as
iPSC, EGC and ECC cell lines. cDNA from wild type mouse testis and lung were used as positive and negative controls, respectively. (D) Western blot
analysis showing the expression of GC markers (Stella, Fragilis), PrM markers (Dmc1, Dazl, MVH) in two different female ESC lines (MPI VI, ES Rosa26).
a-tubulin was used as loading control in A, B and D.
doi:10.1371/journal.pone.0022413.g001
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Nanogappearedonlyonday18and20,respectively and increasedto
levels observed in ES cells only in fully reprogrammed and
established iPS cells (Fig. 5G). Surprisingly, we could not detect
significant expression of pre-meiotic markers such as Stra8, Dazl and
MVH before day 22 of reprogramming. The expression of Stra8
appeared not until day 22 and the other two markers were only
present in established iPS cells (Fig. 5G).
Figure 4. Epigenetic signature of GC/PrM genes in ESCs and iPSCs. ChIP and subsequent real time qPCR for various histone modifications
(active: H3K4me3 and H3K9ac; repressive: H3K9me3 and H3K27me3) at the promoter regions of GC (Fragilis and Blimp1) and PrM markers (Dazl and
MVH) in ESCs (A) and iPSCs (B). The promoter regions of GC markers are similar to the Oct3/4 promoter and are enriched for active histone
modifications, while the promoters of PrM markers are similar to the promoters of the lineage specific genes Hoxa11, Pax5 and were enriched for
both active and repressive marks indicating their bivalent chromatin structure. The qPCR data of two biological replicates (including three technical
replicates each) were calculated and represented as a mean 6SD.
doi:10.1371/journal.pone.0022413.g004
Figure 3. Effect of the downregulation of PrM genes in ESCs. (A and B) Efficiency of Dazl down-regulation as shown by Western blot analysis
and subsequent densitometric qunatification. (C) Real time qPCR analysis showing Dazl downregulation at the RNA level and the expression profile
of the core pluripotency network (Oct3/4, Klf4, Nanog, Zfp206 and Lin28). (D) Expression of GC (Stella and Fragilis) and PrM (MVH and Stra8) markers in
Dazl down-regulated ESCs. (E and F) Western blot showing the efficiency of MVH downregulation and the densitometric quantification, respectively.
(G) Real time qPCR analysis showing MVH downregulation at the RNA level and the expression profile of the core pluripotency network (Oct3/4, Klf4,
Nanog, Zfp206 and Lin28). (H) Expression of GC (Stella and Fragilis) and PrM (Dazl and Stra8) markers in MVH down-regulated ESCs. The dotted lines in
C, D, G, H indicate the normalized expression levels of analyzed genes in control siRNA treated cells. The qPCR data of two biological replicates
(including three technical replicates each) were calculated and represented as a mean 6SD. Expression levels, which are statistically significant, are
indicated with asterisks (**p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0022413.g003
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Though traditionally pluripotent ES cells are regarded as in-vitro
counterpart of the inner cell mass (ICM), their origin is not yet
clearly defined. Recently, it has been hypothesized that ESCs may
have a germ-cell origin based on common molecular properties
with other pluripotent cells of germ-cell origin [9]. Previously, ES
cells were shown to express several GC/PrM markers [15,16,17].
In agreement with these results, that demonstrated the expression
of several GC/PrM markers at the transcript level, our Western
blot analysis detected the expression of GC/PrM markers in all
analyzed pluripotent cell types available including iPS cells and
female ES cells of mouse origin. Consistent with an earlier report
[27], expression of GC/PrM genes was not detectable in bone
marrow-derived multipotent stem cells, thus indicating the unique
expression of GC/PrM genes only in pluripotent cells. Our
immunocytochemistry expression analysis of GC/PrM markers in
preimplantation embryos revealed the expression of Stella, Dazl
and MVH in all analyzed preimplantation embryo stages (2-, 4-, 8-
cell stage). Further, down-regulation of PrM genes in ESCs did not
influence the expression levels of pluripotency network genes, but
rather increase expression of GC genes. Conversely, down-
regulation of pluripotency marker Oct3/4 showed no significant
effect on GC/PrM marker genes, thus highlighting the mainte-
nance of parallel but independent networks.
The genome-wide expression profiling of ES cells revealed the
expression of a large number of genes at low levels due to the open
chromatin state of ES cells leading to leaky expression
[28,29,30,31]. To elucidate leaky versus essential expression of
GC/PrM markers in ES cells, we analyzed the global ChIP-Seq
data of ES cells and found an active chromatin state at PGC/germ
cell markers and a bivalent chromatin structure at pre-meiotic
markers [26]. In support of global ChIP-seq data, our gene-
specific chromatin state of GC/PrM markers in ES cells confirmed
the active chromatin state with enrichment for the activating
histone modifications H3K4me3 and H3K9ac at the promoter
regions of PGC markers Blimp1 and Fragilis, which demonstrates
the fundamental expression of these genes. In contrast, the
promoter regions of Dazl and MVH were marked with bivalent
chromatin state, i.e. enrichment for the two activating (H3K4me3
Figure 6. Hypothetical model for the germ cell origin of pluripotent ESCs. (A) The inner cell mass cells of the blastocyst are positive for
Oct3/4 and Sox2 expression. During further development, primordial germ cell (PGC) specification in mouse implantation embryos (blastocyst
(,E3.5) stage onwards) is marked by the expression of germ cell markers Blimp1 and Fragilis followed by reactivation of Oct3/4 and Sox2 and is
completed by ,E6.5-E7.5 in vivo. This period of in vivo PGC specification parallels with the in vitro ESCs generation from pre-implantation blastocysts
(,E3.5) together with 3–5 days of ESCs outgrowth. (B) On the other hand, reprogramming of somatic cells to iPS cells using the four Yamanaka
factors (Oct3/4, Sox2, Klf4 and c-Myc) leads to the early appearance of germ cell markers followed by the activation of endogenous Oct3/4 and Sox2
and subsequent establishment of pluripotent state. This pattern of gene activation is equivalent to that of PGC specification and ESC establishment
as discussed above. (C) The active chromatin state of germ cell markers in ESCs might indicate the developmental origin of ESCs from PGCs; the
presence of bivalent chromatin at the promoter regions of pre-meiotic genes indicate the poised state for germ line commitment.
doi:10.1371/journal.pone.0022413.g006
Figure 5. Expression pattern of GC/PrM and pluripotency genes during the course of iPS generation. Fully reprogrammed and
established iPS cells express Nanog promoter-driven EGFP (A), positive for AP staining (B), and express SSEA1 (C). (D) Expression of key pluripotency
markers Oct3/4 and Sox2 in iPS cells. Protein extract from ESCs was used as a positive control. (E) Schematic diagram depicting the generation of iPS
cells using the four Yamanaka factors and the time course of sample collection (starting from the day of retrovirus transduction, day0 (d0) till day22
(d22)) for gene expression analysis. (F) Real time qPCR analysis of pluripotency (Oct3/4, Sox2, Nanog and Zfp206), germ cell (Stella, Blimp1 and Fragilis)
and pre-meiotic genes (Dazl, MVH and Stra8) during the time course of iPS cell generation from day5 (5d) to day 10 (10d) after virus infection. Nanog-
EGFP MEFs were used as a control. (G) Real time qPCR analysis for the above mentioned genes during the time course of iPS cell generation from
day12 (12d) to day 22 (22d) after virus infection. The qPCR data of two or more biological replicates (including three technical replicates each) were
calculated and represented as a mean 6SD.
doi:10.1371/journal.pone.0022413.g005
Germ-Cell Markers in Pluripotent Cells
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22413and H3K9ac) and the repressive (H3K27me3) histone modifica-
tions, which is a hallmark of key developmental regulation/lineage
specific genes [32,33]. The observed active chromatin state at GC
marker genes might indicate the possible early germ cell
specification epigenetic marks in pluripotent cells. Conversely,
the bivalent chromatin state at PrM marker genes might represent
the poised germ cell lineage specification or the heterogeneous
expression of these genes in pluripotent cells.
Recent advances in direct reprogramming of somatic cells to
induced pluripotency opened new avenues not only for tailor-
made patient-specific cells for future regenerative medicine in
addition to advancing our knowledge of the basic biology of
establishment and maintenance of pluripotency [34]. Of particular
interest is the role of GC/PrM markers during iPS cell generation
using the four Yamanaka’s factors. We analyzed the activation of
GC/PrM markers along with the endogenous activation of core
pluripotency markers during somatic reprogramming and found
the activation of the PGC specification markers Blimp1, Stella and
Fragilis to occur much earlier (between day 6 and day 9 of
reprogramming) than activation of the endogenous pluripotency
markers Oct3/4 and Sox2 (by day12 of reprogramming). In
contrast, the expression of the PrM markers Dazl, MVH and Stra8
was only detectable by day 22 and in established iPS cell lines,
respectively. Recent studies of the molecular mechanisms
underlying somatic reprogramming revealed that somatic cells
undergo mesenchymal to epithelial transition (MET) during early
reprogramming to acquire pluripotency through BMP signaling
and vital expression of E-cadherin [35,36]. Interestingly, during
embryonic development, PGC precursors rely on inductive BMP
signals followed by MET activation and Fragilis, Blimp1, Stella
and E-cadherin expression [37,38]. Loss of BMP signals, Blimp1
and E-cadherin expression results in the depletion or a reduced
number of PGCs [38,39,40,41]. Taken together, we assume that
even somatic cells acquire a ‘‘temporary’’ PGC/GC fate and
finally establish pluripotency during reprogramming.
Based on our study and earlier reports [9], we propose a
working model for the germ-cell origin of ESCs and the possible
acquisition of PGC/GC fate by somatic cells during iPSCs
generation (Fig. 6). According to our model, the ICM of
blastocyst stage embryos (,E3.5) expresses key pluripotency
markers Oct3/4, Sox2, and c-Myc. Following embryonic
development, PGC specification in-vivo is marked by the
expression of key PGC genes, where Blimp1 is activated by
BMP signaling [10], facilitates the activation of Stella and E-
cadherin, initiates the repression of the somatic program, and
reactivates the pluripotency network before PGCs acquire
migratory properties [38] (Fig. 6A). Considering the GC fate
and lineage commitment of PGCs, key germ-cell markers may
have active chromatin, whereas PrM genes may show bivalent
chromatin (Fig. 6C). Similarly, ESC generation also starts with
isolation of ,E3.5 blastocysts followed by culture to obtain
outgrowth from the ICM. It is more likely that during the in-vitro
ICM outgrowth, ICM cells proceed with the pre-programmed
developmental program of PGC specification via BMP signals,
initiate MET, begin expressing Fragilis, Blimp1, and Stella, re-
activate pluripotency genes, and acquire the unique self-renewal
property (Fig. 6A). The observed active chromatin state of Blimp1,
Stella, and Fragilis thus might indicate the unique expression or
PGC/GC origin of ESC and the bivalent chromatin state of Dazl
and MVH confers the germ-cell lineage commitment, as has been
observed for other lineages (Fig. 6C). Similarly, during somatic
reprogramming, addition of Oct3/4, Sox2, c-Myc, and Klf4 to
somatic cells might mimic the in-vivo ,E3.5 blastocyst ICM cells
and follows the induction of BMP signaling and hence the
activation of Fragilis, Blimp1, Stella, and E-cadherin, and MET
(Fig. 6B). Further, activation of the endogenous pluripotency
network from the host cell genome finally establishes pluripotent
cell characteristics (Fig. 6B). Finally, the chromatin state of GC/
PrM markers may also reflect their transition through germ-cell
fate (Fig. 6C).
In summary, we show the expression of GC/PrM markers in all
analyzed pluripotent cell types and show parallel but independent
maintenance of GC/PrM networks from pluripotent networks.
Through our data, we propose a hypothetical model for possible
germ-cell origin of ESCs and suggest the plausible transition of
somatic cells through germ-cell fate to achieve pluripotency.
Further genetic and epigenetic studies aimed at PGC specification
during ICM outgrowth may resolve and increase our knowledge of
pluripotency.
Supporting Information
Figure S1 Effect of the downregulation of Oct3/4 in ES
cells. (A) Real time qPCR demonstrating the down-regulation of
Oct3/4 and the expression profile of other pluripotency markers
(Klf4, Nanog, Zfp206 and Lin28). (B) Expression profile of germ cell
(Stella and Fragilis) and pre-meiotic (Dazl, MVH and Stra8) markers
in Oct3/4 down-regulated ESCs. The dotted lines indicate the
normalized expression levels of analyzed genes in control siRNA
treated cells. The qPCR data of two biological replicates (including
three technical replicates each) were calculated and represented as
a mean 6SD. Expression levels, which are statistically significant,
are indicated with asterisks (***p,0.001).
(TIF)
Figure S2 Epigenetic signature of pluripotency and GC/
PrM genes in ES cells. (A) Chip-seq data from the database
showing that the promoter regions (red box) of pluripotency
marker gene Oct3/4 and germ cell markers Blimp1 (Prdm1), Stella
(Dppa3) and Fragilis (Ifitm3) representing open chromatin with
abundance of active histone modification H3K4me3 (green peaks)
and are depleted of repressive marks like H3K27me3 and
H3K9me3 (highlighted with red and brown peaks respectively).
In contrast, the promoter regions of pre-meiotic genes MVH
(Ddx4), Dazl, Hoxa11 and Pax5 were marked with both active and
repressive histone modification marks, signifying their bivalent
chromatin structure (B).
(TIF)
Figure S3 Histopathological analysis identifies iPS cell-
derived tumors as teratomas. T u m o r sg r o w ni nR A G 2
2/2
ccc
2/2 mice after injection of iPS cell lines #xu2 and #xu6 were HE
stained. The tumors are teratomas showing ectodermal mesodermal
and endodermal differentiations (* skin epithelium, # cartilage, R
muscle, c gut epithelium). The scale bar represents 100 mm.
(TIF)
Table S1 Primers used in RT-PCR.
(DOC)
Table S2 Quantitative real-time PCR primers for
siRNA down regulation study.
(DOC)
Table S3 Quantitative real-time PCR primers used to
test endogenous gene expression.
(DOC)
Table S4 List of antibodies used in Western blotting.
(DOC)
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